



## ASX Release

12 December 2025

### **Divestment of Prilocaine 2.5% and Lidocaine 2.5%, Cream**

---

**Melbourne, Australia; Acrux Limited (ASX:ACR):** Acrux regularly reviews each product in its portfolio of topical, generic drugs to optimise its return on assets. A recent review, highlighted several products which are demonstrating growing revenue streams, specifically Nitroglycerine 0.4%, Ointment, Dapsone 5%, Gel and Dapsone 7.5%, Gel.

Pridocaine 2.5% and Lidocaine 2.5%, Cream, is however no longer contributing materially to Acrux's portfolio performance. Therefore, the registration and distribution rights in the US for this product (ANDA) has been divested to our distributor for US\$ 550,000.

These proceeds will be received in December 2025 and will be used to support the continued development of Hormone Replacement Therapy products, commonly referred to as HRT.

Authorised for release by the Board of Acrux Limited.

#### **For more information, please contact:**

**John Warmbrunn**

**Acrux Limited**

**CEO & Managing Director**

P: + 61 3 8379 0100

E: [john.warmbrunn@acrux.com.au](mailto:john.warmbrunn@acrux.com.au)

#### **About Acrux**

Acrux is a dynamic Australian drug delivery company developing and commercialising patient preferred healthcare products for global markets.

Economic value at Acrux is created by talented people who effectively develop and commercialise healthcare products using invented or acquired technologies Acrux's products are patient preferred, protected by patent or other means, using innovative drug delivery

For further information on Acrux, visit [www.acrux.com.au](http://www.acrux.com.au)